Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy,,in children and young adults with osteosarcoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 1, 2012, Pages 39-49

  Im, Hyung Jun ^a   Kim, Tae Sung ^a   Park, Seog Yun ^a   Min, Hye Sook ^a   Kim, June Hyuk ^a   Kang, Hyun Guy ^a   Park, Seung Eun ^a   Kwon, Mi Mi ^a   Yoon, Jong Hyung ^a   Park, Hyeon Jin ^a   Kim, Seok Ki ^a   Park, Byung Kiu ^a  

^a National Cancer Center   (South Korea)

Author keywords

18F FDG PET CT; Combined metabolic volumetric indices; Early PET CT response; Osteosarcoma; Response to neoadjuvant chemotherapy

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; IFOSFAMIDE; METHOTREXATE; DIAGNOSTIC AGENT; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3;

ADOLESCENT; ADULT; ARTICLE; BONE NECROSIS; CANCER ADJUVANT THERAPY; CANCER PATIENT; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONE BEAM COMPUTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MEGADOSE; DRUG TUMOR LEVEL; FEMALE; GLYCOLYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; PREDICTION; PREDICTIVE VALUE; PROSPECTIVE STUDY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR NECROSIS; TUMOR VOLUME; ADJUVANT THERAPY; BONE TUMOR; CLINICAL TRIAL; GENE EXPRESSION REGULATION; METABOLISM; NECROSIS; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; SCINTISCANNING; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; COHORT STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 3; GLYCOLYSIS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NECROSIS; NEOADJUVANT THERAPY; OSTEOSARCOMA; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; ROC CURVE; TREATMENT OUTCOME; TUMOR BURDEN; YOUNG ADULT;

EID: 84858781687     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1936-4     Document Type: Article

References (28)

1. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314:1600-6. (Pubitemid 16118216)
2. Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M, Picci P. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer. 2005;41:2836-45. (Pubitemid 41713121)
3. Fletcher BD. Response of osteosarcoma and Ewing sarcoma to chemotherapy: imaging evaluation. AJR Am J Roentgenol. 1991;157:825-33.
4. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5-15.
5. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776-90. (Pubitemid 34111386)
6. Salzer-Kuntschik M, Brand G, Delling G. Determination of the degree of morphological regression following chemotherapy in malignant bone tumors. Pathologe. 1983;4:135-41.
7. Raymond AK, Chawla SP, Carrasco CH, Ayala AG, Fanning CV, Grice B, et al. Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol. 1987;4:212-36.
8. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004;78:1152-60. (Pubitemid 39303827)
9. Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;21:2651-7. (Pubitemid 46606307)
10. Brun E, Kjellen E, Tennvall J, Ohlsson T, Sandell A, Perfekt R, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002;24:127-35. (Pubitemid 34111509)
11. Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D, et al. Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18:1689-95. (Pubitemid 30220547)
12. Ye Z, Zhu J, Tian M, Zhang H, Zhan H, Zhao C, et al. Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET. Ann Nucl Med. 2008;22:475-80.
13. Hawkins DS, Rajendran JG, Conrad 3rd EU, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D- glucose positron emission tomography. Cancer. 2002;94:3277-84. (Pubitemid 34670512)
14. Schulte M, Brecht-Krauss D, Werner M, Hartwig E, Sarkar MR, Keppler P, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med. 1999;40:1637-43. (Pubitemid 29471153)
15. Benz MR, Allen-Auerbach MS, Eilber FC, Chen HJ, Dry S, Phelps ME, et al. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med. 2008;49:1579-84.
16. Picci P, Bacci G, Campanacci M, Gasparini M, Pilotti S, Cerasoli S, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer. 1985;56:1515-21.
17. Picci P, Sangiorgi L, Rougraff BT, Neff JR, Casadei R, Campanacci M. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol. 1994;12:2699-705. (Pubitemid 24379659)
18. Biehl KJ, Kong FM, Dehdashti F, Jin JY, Mutic S, El Naqa I, et al. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate? J Nucl Med. 2006;47:1808-12. (Pubitemid 47545003)
19. Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2:159-71.
20. Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med. 2001;42:1551-5. (Pubitemid 32953137)
21. Lee JD, Yang WI, Park YN, Kim KS, Choi JS, Yun M, et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased 18F-FDG uptake. J Nucl Med. 2005;46:1753-9. (Pubitemid 46211600)
22. Tian M, Zhang H, Nakasone Y, Mogi K, Endo K. Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol Imaging. 2004;31:5-12. (Pubitemid 38133535)
23. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti III A. Bone. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti III A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. 281-90.
24. Costelloe CM, Macapinlac HA, Madewell JE, Fitzgerald NE, Mawlawi OR, Rohren EM, et al. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med. 2009;50:340-7.
25. Cheon GJ, Kim MS, Lee JA, Lee S-Y, Cho WH, Song WS, et al. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI. J Nucl Med. 2009;50:1435-40.
26. Denecke T, Hundsdörfer P, Misch D, Steffen I, Schönberger S, Furth C, et al. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters. Eur J Nucl Med Mol Imaging. 2010;37:1842-53.
27. Hawkins DS, Conrad 3rd EU, Butrynski JE, Schuetze SM, Eary JF. [F-18]-Fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer. 2009;115:3519-25.
28. Hayashida Y, Yakushiji T, Awai K, Katahira K, Nakayama Y, Shimomura O, et al. Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: initial results. Eur Radiol. 2006;16:2637-43. (Pubitemid 44823917)